HAIFA, Israel - Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR), a biotech company specializing in cell-based technologies, has announced the appointment of attorney James Roosevelt Jr. to its Advisory Board. Roosevelt, with a notable background in public service and as the former CEO of Tufts Health Plan, brings a wealth of experience in healthcare policy and business strategy to the company.
Roosevelt's career has been characterized by his advocacy for equitable healthcare access and his leadership at Tufts Health Plan, which was recognized for its quality of care under his tenure. His expertise is expected to aid Pluri's strategic growth, particularly in regenerative medicine. His role will involve advising on securing grants, contracts with U.S. government agencies, and fostering investor and partner relationships.
Pluri's CEO and President, Yaky Yanay, expressed confidence in Roosevelt's ability to contribute to the company's growth due to his understanding of regenerative medicine and proprietary technology. Zami Aberman, chairman of the board, anticipates that Roosevelt's insights will enhance the development of personalized cell therapies.
Prior to his role at Tufts Health Plan, Roosevelt served as associate commissioner of the U.S. Social Security Administration. He is also recognized for his work as a national speaker, author on healthcare policy, and his involvement in various public service and educational roles.
Pluri Inc. is known for its patented 3D cell expansion system, which is touted for its precision, scalability, cost-effectiveness, and consistency. The company operates in regenerative medicine, food-tech, and agtech, with ambitions to extend its cell-based technology to other industries.
This appointment is part of Pluri's mission to develop new cell-based treatments for populations with unmet medical needs. The company's forward-looking statements reflect its aspirations but are subject to various factors and uncertainties that could impact actual outcomes.
The information in this article is based on a press release statement from Pluri Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.